Erlotinib and Temsirolimus for Solid Tumors
Define the maximum tolerated dose and dose limiting side-effects of temsirolimus in combination wtih erlotinib in patients with resistant solid tumors
Solid Tumors
DRUG: Erlotinib|DRUG: Temsirolimus
To define the maximum tolerated dose and dose-limiting toxicities of temsirolimus in combination with erlotinib in patients with resistant solid malignancies., 3 years for MTD to be determined, DLT occurs in 1st cycle only|To determine the incidence and severity of other toxicities of temsirolimus in combination with erlotinib in patients with resistant solid malignancies., 30 days after end of treatment
To assess the pharmacodynamic profile of temsirolimus in combination with erlotinib., Prior to each cycle|To determine any anti-tumor activity and response to the combination of temsirolimus and erlotinib in treatment of patients with resistant solid malignancies., End of treatment|To evaluate the relation between pS6K1 and p-Akt to clinical response to temsirolimus., End of treatment
Define the maximum tolerated dose and dose limiting side-effects of temsirolimus in combination wtih erlotinib in patients with resistant solid tumors